{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:36:21Z","timestamp":1788496581038,"version":"build-2803163510"},"reference-count":25,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100000659","name":"Research Trainees Coordinating Centre","doi-asserted-by":"publisher","award":["CL-2021-06-007"],"award-info":[{"award-number":["CL-2021-06-007"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pickering Fellowship, North West Lung Centre Charity","award":["No award\/grant number"],"award-info":[{"award-number":["No award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In real-world chronic obstructive pulmonary disease (COPD) care, poor adherence often leads to treatment discontinuations. Discontinuing inhaled corticosteroids (ICS) can trigger withdrawal effects transiently increasing exacerbation risk; but evidence for long-acting muscarinic antagonists (LAMA) withdrawal remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that compared long-acting beta-2 agonist (LABA)+LAMA with LABA+ICS in 3362 patients with moderate-to-severe COPD and exacerbation history. Potential withdrawal effects after discontinuing LAMA or ICS were suggested by monthly exacerbation incidence plots during the first quarter of follow-up. Participants were stratified by their baseline use of these therapies, and outcomes were compared between the first and subsequent quarters among those who continued versus discontinued each treatment. Multivariable mixed-effects models assessed differences in exacerbation rates, with temporal variation in treatment effects interpreted as indicative of withdrawal effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Discontinuing LAMA was associated with a marked, transient increase in moderate-to-severe exacerbations during the first versus subsequent quarters (p=0.001; rate ratio up to 2.2 (95% CI 1.2 to 4.1) in the subgroup least influenced by concomitant ICS use). This observation was not confirmed for severe exacerbations, likely due to low event count. In contrast, discontinuing ICS was associated with a significant early rise in severe exacerbations (p=0.023), though the difference for moderate-to-severe events did not reach statistical significance. Importantly, ICS withdrawal effects appeared consistent regardless of baseline blood eosinophil count.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01782326\">NCT01782326<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223282","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:25:21Z","timestamp":1765869921000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial"],"prefix":"10.1136","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct01782326","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-9616","authenticated-orcid":false,"given":"Alexander G","family":"Mathioudakis","sequence":"first","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bate","sequence":"additional","affiliation":[{"name":"Research and Innovation, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK"},{"name":"Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care, Facutly of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chatzimavridou-Grigoriadou","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrik St\u00e6hr","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar Diar","family":"Bakerly","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"Department of Medicine, Section of Respiratory Medicine, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Immunology, Immunity to Infection and Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK"},{"name":"North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, England, UK"},{"name":"Medicines Evaluation Unit an IQVIA business, Wythenshawe, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026051403202041000_81.6.533.1","doi-asserted-by":"crossref","unstructured":"Collaborators GBDCoD . Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;2100\u201332. doi:10.1016\/S0140-6736(24)00367-2","DOI":"10.1016\/S0140-6736(24)00367-2"},{"key":"2026051403202041000_81.6.533.2","doi-asserted-by":"crossref","unstructured":"Diseases GBD, Injuries C . Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;2133\u201361. doi:10.1016\/S0140-6736(24)00757-8","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"2026051403202041000_81.6.533.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00239-2023","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"61","author":"Agust\u00ed","year":"2023","journal-title":"Eur Respir J"},{"key":"2026051403202041000_81.6.533.4","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0267-2022","article-title":"Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022","volume":"19","author":"Stolz","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026051403202041000_81.6.533.5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01655-2017","article-title":"Precision medicine in airway diseases: moving to clinical practice","volume":"50","author":"Agust\u00ed","year":"2017","journal-title":"Eur Respir J"},{"key":"2026051403202041000_81.6.533.6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccm.2020.05.005","article-title":"Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?","volume":"41","author":"Mathioudakis","year":"2020","journal-title":"Clin Chest Med"},{"key":"2026051403202041000_81.6.533.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.3790"},{"key":"2026051403202041000_81.6.533.8","doi-asserted-by":"crossref","first-page":"32108044","DOI":"10.1183\/13993003.02119-2019","article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD","volume":"55","author":"Mathioudakis","year":"2020","journal-title":"Eur Respir J"},{"key":"2026051403202041000_81.6.533.9","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0260-2022","article-title":"Impact of triple therapy on mortality in COPD","volume":"19","author":"Soumagne","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026051403202041000_81.6.533.10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026051403202041000_81.6.533.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00098307"},{"key":"2026051403202041000_81.6.533.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00198.x"},{"key":"2026051403202041000_81.6.533.13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09059180.05.00009604","article-title":"Patient adherence with COPD therapy","volume":"14","author":"Rand","year":"2005","journal-title":"Eur Respir Rev"},{"key":"2026051403202041000_81.6.533.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191811573","article-title":"Treatment Adherence in Patients with Obstructive Pulmonary Diseases","volume":"19","author":"Hom\u0119towska","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026051403202041000_81.6.533.15","doi-asserted-by":"crossref","first-page":"108465","DOI":"10.1016\/j.pec.2024.108465","article-title":"Path analysis of illness perception, medication beliefs, family support on inhaler adherence in elderly COPD patients: Based on triadic reciprocal determinism","volume":"130","author":"Liu","year":"2025","journal-title":"Patient Educ Couns"},{"key":"2026051403202041000_81.6.533.16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2147\/COPD.S460903","article-title":"Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study","volume":"19","author":"Vogelmeier","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026051403202041000_81.6.533.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"},{"key":"2026051403202041000_81.6.533.18","doi-asserted-by":"crossref","first-page":"17534666221107314","DOI":"10.1177\/17534666221107314","article-title":"Predictive modeling of COPD exacerbation rates using baseline risk factors","volume":"16","author":"Singh","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026051403202041000_81.6.533.19","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222547"},{"key":"2026051403202041000_81.6.533.20","doi-asserted-by":"crossref","first-page":"32366483","DOI":"10.1183\/13993003.00351-2020","article-title":"Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline","volume":"55","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"key":"2026051403202041000_81.6.533.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407154"},{"key":"2026051403202041000_81.6.533.22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026051403202041000_81.6.533.23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-Term Triple Therapy De-escalation to Indacaterol\/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026051403202041000_81.6.533.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715275"},{"key":"2026051403202041000_81.6.533.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:21:59Z","timestamp":1778754119000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,14]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/thorax-2025-223282"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223282","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}